Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest MorphoSys Stories

2013-04-16 12:26:37

DUBLIN, Ireland, April 16, 2013 /PRNewswire/ -- Research and Markets announces the addition of "Antibody Technologies and Attrition Rates - an industry analysis 2013 [http://www.researchandmarkets.com/research/7rg77r/antibody ]" to its catalogue. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The report Antibody Technologies and Attrition Rates - an industry analysis 2013 is based on the identification of the antibody generation technologies of 504...

2013-04-16 08:28:59

MONROVIA, Calif. and MELBOURNE, Australia, April 16, 2013 /PRNewswire/ -- Xencor, Inc. announced today that Xencor and CSL Limited have entered into a technology license agreement to provide CSL access to Xencor's Xtend technology to optimize the performance of CSL's monoclonal antibodies. Under the agreement CSL will be granted an exclusive license to utilize Xencor's proprietary Xtend(TM) half-life extension technology in its program against an undisclosed target. Xencor will receive an...

2013-04-02 12:31:23

WELWYN GARDEN CITY, England and BOSTON, April 2, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery company, notes that Dan Grau (Heptares' President) will attend the Boston Biotech BD Conference [http://bbbiotechconference.com/conference-agenda.php?id=10 ] taking place at the Four Seasons Hotel, Boston, MA, USA (2-3 April), at which he will participate in a panel discussion entitled Listening to Patients While Setting Company Goals: More Important...

2013-03-01 12:25:00

WELWYN GARDEN CITY, England and BOSTON, March 1, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery company, announces that Malcolm Weir (Heptares CEO) will attend the 6th Annual European Life Science CEO Forum [http://www.sachsforum.com/zurich_elsceo13/index.html ] taking place on the at the Hilton Zurich Airport Hotel, Zurich, Switzerland (5-6 March), at which he will participate in a panel discussion on Platform Technologies and Novel Therapeutics...

2013-02-13 08:27:48

MONROVIA, Calif., Feb. 13, 2013 /PRNewswire/ -- Xencor, Inc. today announced that the first patient has been dosed in a Phase 1b/2a clinical trial of XmAb®5871 in patients with moderate to severe rheumatoid arthritis. XmAb5871 is the first in a new class of therapeutic antibodies targeting the CD32b (FcgRIIb) pathway in B cells, which shows potential to suppress autoimmune disorders without the side effects caused by B cell depletion. The trial initiation triggered a milestone payment of...

2013-02-13 04:20:34

MARTINSRIED and MUNICH, Germany, WELWYN GARDEN CITY, England and BOSTON, February 13, 2013 /PRNewswire/ -- Collaboration Harnesses Heptares' StaRs(R) to Open up New Target Space for Therapeutic Antibodies from MorphoSys' Ylanthia(R) Platform MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, have signed an agreement to discover novel antibody...

2013-01-17 08:26:25

MONROVIA, Calif., Jan. 17, 2013 /PRNewswire/ -- Xencor, Inc. today announced it has received a milestone payment from Janssen Research & Development, LLC (Janssen R&D) resulting from the exercised option for the use of Xencor's Xtend(TM) half-life extension technology in a therapeutic antibody. This triggered a payment to Xencor under the terms of a technology license agreement that the company entered into with Janssen R&D (f/k/a Centocor Research & Development, Inc.) in...

2012-11-05 12:26:12

MARTINSRIED, Germany and MUNICH and MONROVIA, Calif., Nov. 5, 2012 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and US-based Xencor, Inc. today announced the online publication of first clinical data on the anti-CD19 antibody MOR208 (MOR00208/XmAb5574) in the American Society of Hematology Annual Meeting Abstracts issue of the peer-reviewed medical journal Blood. MOR208 showed encouraging signs of preliminary anti-tumor activity and an acceptable...

2012-08-15 18:20:41

BURLINGAME, Calif., Aug. 15, 2012 /PRNewswire/ -- Apexigen, Inc., an emerging biopharmaceutical company focused on the discovery and development of monoclonal antibody therapeutics, announced today that its partner, 3SBio [SSRX] of Shenyang, China, filed an Investigational New Drug (IND) application for APX001, also known as SSS07, with the State Food and Drug Administration (SFDA) in China. Upon approval of the IND, APX001/SSS07 will be studied in clinical trials for the treatment of...

2012-05-21 22:20:52

MARTINSRIED and MUNICH, Germany, and MONROVIA, Calif., May 22, 2012 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208. MOR208 (formerly XmAb®5574) is a potent anti-CD19 antibody with a proprietary modification to the Fc portion, that is being developed to treat B-cell malignancies. A total of 30 patients with relapsed or refractory...